Woodside Biopharma

Woodside Biopharma is a biotechnology company focused on the development of novel cannabinoid-based therapeutics. The company leverages its expertise in medicinal chemistry and pharmacology to design proprietary small molecules that target the endocannabinoid system, specifically focusing on CB1 and CB2 receptors. Their research aims to address significant unmet needs in chronic pain management and inflammatory conditions while minimizing the psychoactive side effects typically associated with cannabinoid therapies. Woodside Biopharma is currently in the pre-clinical stage, advancing its lead candidates through optimization and early safety profiling.